Immuron Limited (IMC.AX)
AUD 0.07
(0.0%)
AUD 0.07
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 3.33 Million AUD | 154.88% |
| 2023 | 1.3 Million AUD | 150.07% |
| 2022 | 523.5 Thousand AUD | 452.77% |
| 2021 | 94.7 Thousand AUD | -94.82% |
| 2020 | 1.82 Million AUD | 7.21% |
| 2019 | 1.7 Million AUD | 35.38% |
| 2018 | 1.26 Million AUD | 36.7% |
| 2017 | 922.15 Thousand AUD | 32.6% |
| 2016 | 695.46 Thousand AUD | 6.84% |
| 2015 | 650.91 Thousand AUD | -0.31% |
| 2014 | 652.91 Thousand AUD | 1600.89% |
| 2013 | -43.5 Thousand AUD | -151.0% |
| 2012 | 85.29 Thousand AUD | 3270.82% |
| 2011 | -2690.00 AUD | -101.44% |
| 2010 | 186.46 Thousand AUD | -46.9% |
| 2009 | 351.16 Thousand AUD | 1505.55% |
| 2008 | 21.87 Thousand AUD | -94.78% |
| 2007 | 418.89 Thousand AUD | -70.61% |
| 2006 | 1.42 Million AUD | 164.71% |
| 2005 | -2.2 Million AUD | -266.5% |
| 2004 | 1.32 Million AUD | 0.0% |
| 2003 | - AUD | -100.0% |
| 2002 | 618.75 Thousand AUD | 289.87% |
| 2001 | -325.88 Thousand AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 FY | 3.33 Million AUD | 154.88% |
| 2024 Q2 | 1.58 Million AUD | 0.0% |
| 2024 Q4 | 1.75 Million AUD | 0.0% |
| 2023 FY | 1.3 Million AUD | 150.07% |
| 2023 Q2 | 427.92 Thousand AUD | 0.0% |
| 2023 Q4 | 881.22 Thousand AUD | 0.0% |
| 2022 Q4 | 361.95 Thousand AUD | 0.0% |
| 2022 Q2 | 161.54 Thousand AUD | 0.0% |
| 2022 FY | 523.5 Thousand AUD | 452.77% |
| 2021 Q2 | 7825.00 AUD | 0.0% |
| 2021 FY | 94.7 Thousand AUD | -94.82% |
| 2021 Q4 | 86.88 Thousand AUD | 0.0% |
| 2020 Q2 | 1.12 Million AUD | 0.0% |
| 2020 FY | 1.82 Million AUD | 7.21% |
| 2020 Q4 | 708.3 Thousand AUD | 0.0% |
| 2019 FY | 1.7 Million AUD | 35.38% |
| 2019 Q4 | 970.66 Thousand AUD | 0.0% |
| 2019 Q2 | 746.75 Thousand AUD | 0.0% |
| 2018 Q4 | 700.43 Thousand AUD | 0.0% |
| 2018 Q2 | 560.18 Thousand AUD | 0.0% |
| 2018 FY | 1.26 Million AUD | 36.7% |
| 2017 Q4 | 577.62 Thousand AUD | 0.0% |
| 2017 FY | 922.15 Thousand AUD | 32.6% |
| 2017 Q2 | 344.53 Thousand AUD | 0.0% |
| 2016 Q4 | 352.05 Thousand AUD | 0.0% |
| 2016 Q2 | 343.41 Thousand AUD | 0.0% |
| 2016 FY | 695.46 Thousand AUD | 6.84% |
| 2015 Q4 | 298.65 Thousand AUD | 0.0% |
| 2015 Q2 | 352.26 Thousand AUD | 0.0% |
| 2015 FY | 650.91 Thousand AUD | -0.31% |
| 2014 Q2 | 279.28 Thousand AUD | 0.0% |
| 2014 FY | 652.91 Thousand AUD | 1600.89% |
| 2014 Q4 | 432.16 Thousand AUD | 0.0% |
| 2013 Q3 | -10.87 Thousand AUD | -118.59% |
| 2013 FY | -43.5 Thousand AUD | -151.0% |
| 2013 Q1 | 21.32 Thousand AUD | -0.0% |
| 2013 Q4 | -24.35 Thousand AUD | -123.92% |
| 2013 Q2 | 58.48 Thousand AUD | 174.3% |
| 2012 Q1 | -672.50 AUD | 0.07% |
| 2012 FY | 85.29 Thousand AUD | 3270.82% |
| 2012 Q4 | 21.32 Thousand AUD | 0.0% |
| 2012 Q3 | 21.32 Thousand AUD | -0.0% |
| 2012 Q2 | 21.32 Thousand AUD | 3270.86% |
| 2011 Q3 | -672.50 AUD | 0.07% |
| 2011 Q4 | -673.00 AUD | -0.07% |
| 2011 FY | -2690.00 AUD | -101.44% |
| 2011 Q2 | -673.00 AUD | -101.44% |
| 2011 Q1 | 46.61 Thousand AUD | 0.0% |
| 2010 Q3 | 46.61 Thousand AUD | 0.0% |
| 2010 FY | 186.46 Thousand AUD | -46.9% |
| 2010 Q4 | 46.61 Thousand AUD | 0.0% |
| 2010 Q2 | 46.61 Thousand AUD | -46.9% |
| 2010 Q1 | 87.79 Thousand AUD | 0.0% |
| 2009 FY | 351.16 Thousand AUD | 1505.55% |
| 2009 Q1 | 5468.00 AUD | 0.0% |
| 2009 Q2 | 87.79 Thousand AUD | 1505.54% |
| 2009 Q3 | 87.79 Thousand AUD | 0.0% |
| 2009 Q4 | 87.79 Thousand AUD | 0.0% |
| 2008 Q1 | 104.72 Thousand AUD | -0.0% |
| 2008 Q2 | 5468.00 AUD | -94.78% |
| 2008 FY | 21.87 Thousand AUD | -94.78% |
| 2008 Q4 | 5468.00 AUD | 0.0% |
| 2008 Q3 | 5468.00 AUD | 0.0% |
| 2007 Q1 | 356.3 Thousand AUD | 0.0% |
| 2007 FY | 418.89 Thousand AUD | -70.61% |
| 2007 Q2 | 104.72 Thousand AUD | -70.61% |
| 2007 Q4 | 104.72 Thousand AUD | 0.0% |
| 2007 Q3 | 104.72 Thousand AUD | -0.0% |
| 2006 Q2 | 356.3 Thousand AUD | 164.71% |
| 2006 Q1 | -550.57 Thousand AUD | -0.0% |
| 2006 Q4 | 356.3 Thousand AUD | 0.0% |
| 2006 Q3 | 356.3 Thousand AUD | 0.0% |
| 2006 FY | 1.42 Million AUD | 164.71% |
| 2005 Q2 | -550.57 Thousand AUD | -266.5% |
| 2005 FY | -2.2 Million AUD | -266.5% |
| 2005 Q4 | -550.57 Thousand AUD | 0.0% |
| 2005 Q3 | -550.57 Thousand AUD | -0.0% |
| 2005 Q1 | 330.66 Thousand AUD | 0.0% |
| 2004 FY | 1.32 Million AUD | 0.0% |
| 2004 Q2 | 330.66 Thousand AUD | 0.0% |
| 2004 Q3 | 330.66 Thousand AUD | 0.0% |
| 2004 Q4 | 330.66 Thousand AUD | 0.0% |
| 2004 Q1 | - AUD | 0.0% |
| 2003 Q1 | 154.68 Thousand AUD | 0.0% |
| 2003 Q2 | - AUD | -100.0% |
| 2003 Q3 | - AUD | 0.0% |
| 2003 Q4 | - AUD | 0.0% |
| 2003 FY | - AUD | -100.0% |
| 2002 Q1 | -81.47 Thousand AUD | 0.0% |
| 2002 Q4 | 154.68 Thousand AUD | 0.0% |
| 2002 Q3 | 154.68 Thousand AUD | 0.0% |
| 2002 Q2 | 154.68 Thousand AUD | 289.87% |
| 2002 FY | 618.75 Thousand AUD | 289.87% |
| 2001 Q3 | -81.47 Thousand AUD | 0.0% |
| 2001 Q4 | -81.47 Thousand AUD | 0.0% |
| 2001 Q2 | -81.47 Thousand AUD | 0.0% |
| 2001 Q1 | - AUD | 0.0% |
| 2001 FY | -325.88 Thousand AUD | 0.0% |
| 2000 Q1 | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 2000 Q4 | - AUD | 0.0% |
| 2000 Q3 | - AUD | 0.0% |
| 2000 Q2 | - AUD | 0.0% |
| 1999 Q2 | - AUD | 0.0% |
| 1999 Q3 | - AUD | 0.0% |
| 1999 Q4 | - AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AdAlta Limited | 1.5 Million AUD | -121.285% |
| Acrux Limited | -1.28 Million AUD | 359.875% |
| Race Oncology Limited | 1.38 Million AUD | -140.072% |
| Biome Australia Limited | 7.66 Million AUD | 56.494% |
| Botanix Pharmaceuticals Limited | -6.55 Million AUD | 150.931% |
| BTC Health Limited | 16.36 Thousand AUD | -20296.07% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 55.233% |
| CSL Limited | 15.28 Billion AUD | 99.978% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 71.001% |
| Clinuvel Pharmaceuticals Limited | 78.09 Million AUD | 95.727% |
| EZZ Life Science Holdings Limited | 50.94 Million AUD | 93.45% |
| Hexima Limited | - AUD | -Infinity% |
| Immutep Limited | 1.44 Million AUD | -131.095% |
| Memphasys Limited | 1606.00 AUD | -207670.672% |
| Neuren Pharmaceuticals Limited | 205.17 Million AUD | 98.374% |
| Noxopharm Limited | -534.81 Thousand AUD | 723.921% |
| Prescient Therapeutics Limited | 3.71 Million AUD | 10.117% |
| Radiopharm Theranostics Limited | -21.3 Million AUD | 115.66% |
| Starpharma Holdings Limited | 7.65 Million AUD | 56.422% |
| Tissue Repair Ltd | 150.51 Thousand AUD | -2116.979% |
| Biotron Limited | -40.49 Thousand AUD | 8339.412% |
| Alterity Therapeutics Limited | 3.8 Million AUD | 12.305% |
| Anatara Lifesciences Ltd | -748.91 Thousand AUD | 545.554% |
| Bio-Gene Technology Limited | -301.44 Thousand AUD | 1206.919% |
| Zelira Therapeutics Limited | 10.28 Thousand AUD | -32346.49% |
| Patrys Limited | 1.39 Million AUD | -139.341% |
| Orthocell Limited | 3.68 Million AUD | 9.533% |
| Imugene Limited | -5.83 Million AUD | 157.138% |
| PYC Therapeutics Limited | 22.05 Million AUD | 84.874% |
| Proteomics International Laboratories Limited | -1.12 Million AUD | 397.082% |
| Cynata Therapeutics Limited | 2.31 Million AUD | -44.098% |
| Arovella Therapeutics Limited | -25.97 Thousand AUD | 12944.209% |
| Nanollose Limited | -348.95 Thousand AUD | 1056.234% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -175.255% |
| NeuroScientific Biopharmaceuticals Limited | -91.33 Thousand AUD | 3753.281% |
| Amplia Therapeutics Limited | 4.01 Million AUD | 16.804% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -166.608% |
| Nyrada Inc. | -5164.07 AUD | 64715.642% |
| Telix Pharmaceuticals Limited | 308.5 Million AUD | 98.918% |
| Dimerix Limited | 583.47 Thousand AUD | -471.881% |
| PharmAust Limited | -1641.00 AUD | 203439.244% |
| AnteoTech Limited | 460.39 Thousand AUD | -624.765% |
| Paradigm Biopharmaceuticals Limited | 56.81 Thousand AUD | -5773.402% |
| Recce Pharmaceuticals Ltd | -366.76 Thousand AUD | 1009.784% |
| Avecho Biotechnology Limited | -43.79 Thousand AUD | 7719.128% |
| Actinogen Medical Limited | 9.93 Million AUD | 66.402% |
| Argenica Therapeutics Limited | 2.59 Million AUD | -28.44% |